OVUM Voices
Longevity claims vs. evidence for women
Which longevity and peptide claims rest on evidence in women, and which do not?
longevity
The gist
Longevity products aimed at women are selling faster than trials in women are published. Contributors separate claims backed by data in women from those borrowed from studies in men or animals.
- 5 published perspectives · 5 adds data
- Latest: Peptides mapped across women's health (Jun 21, 2026)
- 8 related OVUM records on funding, research and policy, each with its source below.
Who is saying what
5 published perspectivesAdds data· Market commentary
Peptides mapped across women's health“Yesterday I mapped where peptides have been used across women's health.”
OVUM EditorialOriginal post on LinkedIn
Adds data· Investor POV
Longevity meets healthtech capital“Longevity healthtech is the fastest-growing capital pool in women's health-adjacent biotech.”
OVUM EditorialOriginal post on LinkedIn
Adds data· Investor POV
Daniel Chappell: longevity real estate is coming“Longevity real estate is coming — and women are the primary customer.”
Adds data· Investor POV
NewLimit on longevity biotech and women's health“Longevity biotech is quietly becoming women's health biotech.”
OVUM EditorialOriginal post on LinkedIn
Adds data· Data / Research take
Breaking: ovaries have multiple aging mechanisms“Ovaries have multiple, distinct aging mechanisms — not one.”
OVUM EditorialOriginal post on LinkedIn